Seres Therapeutics, Inc.
MCRB
$19.44
$1.126.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 314.74% | -31.22% | |||
| Gross Profit | -314.74% | 31.22% | |||
| SG&A Expenses | -13.75% | -4.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.65% | -5.55% | |||
| Operating Income | 8.65% | 5.55% | |||
| Income Before Tax | -160.75% | 309.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -160.75% | 309.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -160.75% | 309.00% | |||
| EBIT | 8.65% | 5.55% | |||
| EBITDA | 8.94% | 5.73% | |||
| EPS Basic | -160.47% | 305.70% | |||
| Normalized Basic EPS | -2.30% | -1,023.07% | |||
| EPS Diluted | -160.55% | 298.28% | |||
| Normalized Diluted EPS | -2.44% | -1,021.82% | |||
| Average Basic Shares Outstanding | 0.47% | 1.61% | |||
| Average Diluted Shares Outstanding | 0.33% | 1.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||